Breast Cancer Clinical Trials in Denver, Colorado

15 studies are recruiting for breast cancer in Denver, Colorado right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    Rocky Mountain Cancer Center, Denver, Colorado
    Locations
    77 in total
    Run by
    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

  2. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    St. Joseph Hospital-Cancer Centers of Colorado, Denver, Colorado
    Locations
    567 in total
    Run by
    Stemline Therapeutics, Inc.

    See if you can join NCT06492616 on ClinicalTrials.gov

  3. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

    Stage
    Phase 3
    Ages
    18 to 60
    Site
    UCHealth - Cherry Creek, Denver, Colorado
    Locations
    1261 in total
    Run by
    NRG Oncology

    See if you can join NCT05879926 on ClinicalTrials.gov

  4. A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

    This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Rocky Mountain Cancer Centers, Denver, Colorado
    Locations
    210 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT05646862 on ClinicalTrials.gov

  5. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

    Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute - Denver DDU, Denver, Colorado
    Locations
    10 in total
    Run by
    Nammi Therapeutics Inc

    See if you can join NCT06582017 on ClinicalTrials.gov

  6. A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

    The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Rocky Mountain Cancer Centers, Denver, Colorado
    Locations
    35 in total
    Run by
    Jazz Pharmaceuticals

    See if you can join NCT07102381 on ClinicalTrials.gov

  7. A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

    This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inop…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Denver, Colorado
    Locations
    320 in total
    Run by
    AstraZeneca

    See if you can join NCT06103864 on ClinicalTrials.gov

  8. Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

    This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Clinical Trial Site, Denver, Colorado
    Locations
    181 in total
    Run by
    Olema Pharmaceuticals, Inc.

    See if you can join NCT07085767 on ClinicalTrials.gov

  9. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

    This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of car…

    Stage
    Phase 3
    Ages
    18 to 100
    Site
    Rocky Mountain Cancer Centers, Denver, Colorado
    Locations
    179 in total
    Run by
    Greenwich LifeSciences, Inc.

    See if you can join NCT05232916 on ClinicalTrials.gov

  10. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute, Denver, Colorado
    Locations
    6 in total
    Run by
    ModeX Therapeutics, An OPKO Health Company

    See if you can join NCT06239194 on ClinicalTrials.gov

  11. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

    The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Rocky Mountain Cancer Centers LLP, Denver, Colorado
    Locations
    202 in total
    Run by
    Pfizer

    See if you can join NCT07062965 on ClinicalTrials.gov

  12. The Immune System's Response to Young Women's Breast Cancer

    This study plans to learn more about the immune system's response to breast cancer in young women.

    Stage
    Not phased
    Ages
    18 and older
    Site
    Denver Health Hospital Authority, Denver, Colorado
    Locations
    5 in total
    Run by
    University of Colorado, Denver

    See if you can join NCT01503190 on ClinicalTrials.gov

  13. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Denver, Colorado
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  14. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

    This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, cataly…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    HealthONE, Denver, Colorado
    Locations
    37 in total
    Run by
    Relay Therapeutics, Inc.

    See if you can join NCT05216432 on ClinicalTrials.gov

  15. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

    The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enabl…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Comprehensive Breast Care of Denver, Denver, Colorado
    Locations
    134 in total
    Run by
    Agendia

    See if you can join NCT03053193 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.